Skip to main content

Parkinson's Disease

Parkinson disease (PD) and related atypical parkinsonism syndromes (most importantly multiple system atrophy — MSA) are a high-volume but generally non-reconstructive NLUTD population. Symptoms are dominantly storage-phase OAB with preserved coordination, and management is largely pharmacologic and behavioral. The reconstructive urologist's role is mostly diagnostic (distinguishing PD from MSA, from coexisting BPH) and risk-avoidance (anticholinergics in a cognitively vulnerable population, functional incontinence in a mobility-impaired population).

See Neurogenic Lower Urinary Tract Dysfunction for the general framework.

Epidemiology​

  • US prevalence of PD >1 million; incidence rises with age.
  • ~25–40% of PD patients have clinically relevant urinary symptoms.[2]
  • OAB / DO is the dominant phenotype.
  • Urinary symptoms correlate with motor severity and autonomic dysfunction.
  • MSA is much rarer but has a far more aggressive autonomic phenotype — urinary symptoms often precede the motor diagnosis and are severe from onset.

Pathophysiology​

  • PD is a suprapontine disease. Loss of basal ganglia dopaminergic input disinhibits the pontine micturition center, producing detrusor overactivity with preserved coordination (no DSD). Storage pressures are typically low — upper-tract risk is rare.
  • MSA has both suprapontine and sacral involvement. Patients develop early and severe OAB with later retention, DSD-like patterns, and profound sphincter denervation. Urinary retention with elevated PVR is common and an important clue.
  • Coexisting BPH — most PD patients are older men, so mixed PD-OAB + BPH outlet obstruction is common.

Evaluation​

Initial:

  • History — symptom onset vs motor symptom onset (early = MSA red flag), fall risk, medications, cognition, caregiver status.
  • UA, PVR, voiding diary.

Adjunctive (as indicated):

  • Urodynamics — recommended before prostate surgery in men with PD to distinguish outlet obstruction from PD OAB (changes postoperative expectations), and whenever MSA is suspected.
  • Renal US + eGFR in patients with elevated PVR or MSA phenotype.

PD vs MSA — the urologic clue​

FeaturePDMSA
Onset of urinary symptomsLate, follows motorEarly — often before motor
OABYesYes, often severe
PVRUsually lowElevated — early retention
Orthostatic hypotensionModestSevere
Response to dopaminergic therapyGood (motor)Poor
EMG of external anal sphincterNormalDenervation pattern

Early urinary retention + severe orthostatic hypotension + poor dopamine response should raise concern for MSA and change counseling about prognosis and procedure selection.

Management​

Behavioral and pharmacologic first line​

  • Timed voiding, bowel program, fluid management.
  • Pelvic-floor PT — modest benefit in selected patients.
  • β3-adrenergic agonists (mirabegron, vibegron) — first-line pharmacologic in PD because of the cognitive risk of anticholinergics in a vulnerable population.[1]
  • Antimuscarinics — used when β3 inadequate; trospium preferred (minimal CNS penetration). Avoid oxybutynin IR in cognitively impaired patients.
  • Desmopressin — selective use for nocturia; monitor sodium, avoid in frail / older patients with fall risk.

Intradetrusor onabotulinumtoxinA​

  • Effective for refractory PD OAB.
  • Caution: post-injection urinary retention may tip a borderline patient into full retention requiring CIC — many PD patients lack the dexterity for CIC. Discuss explicitly before proceeding.

Prostate / outlet surgery in men with PD​

  • TURP, HoLEP, simple prostatectomy etc. are appropriate when obstruction is documented on urodynamics.
  • Counsel about persistent OAB symptoms post-op — outlet surgery does not fix the neurogenic component.
  • In MSA, outlet surgery is generally contraindicated — worsens incontinence in a patient with already failing sphincter function.

Catheter-based management​

  • Indwelling urethral catheter — sometimes the pragmatic choice in late PD / MSA with severe mobility limitation and caregiver support.
  • CIC — feasible in early PD with intact dexterity; becomes harder as tremor progresses.
  • Suprapubic catheter — preferred over urethral in men for long-term drainage.

Sacral neuromodulation and PTNS​

  • SNM is a reasonable option in PD with refractory OAB.[1]
  • MRI compatibility — PD patients often have co-indications for brain imaging (e.g., if DBS surgery is planned); verify device MRI-conditional status.
  • DBS interaction — for PD patients with deep-brain stimulators, coordinate with the movement-disorders team.
  • Usually not used in MSA because of the aggressive autonomic phenotype.

Reconstructive surgery​

  • Rare in PD. Augmentation is almost never indicated because upper-tract risk is low.
  • MSA — occasionally needs urinary diversion for refractory combined retention and incontinence, but advanced care planning and prognosis often drive the decision.

Common Scenarios​

PD with OAB and mixed BPH​

Pragmatic pathway: (1) β3 agonist + α-blocker; (2) urodynamics if equivocal; (3) outlet surgery for documented obstruction with residual OAB treatment; (4) botulinum only after CIC capacity confirmed.

PD with nocturia​

Very common and multifactorial — fluid intake, peripheral edema redistribution, sleep fragmentation, depression. Treat the modifiable factors first (elevation, compression, evening fluid restriction) before adding desmopressin.

PD with dementia / functional incontinence​

Shifts emphasis to caregiver-directed toileting schedules, incontinence products, and careful medication review (anticholinergic burden, diuretics). Avoid aggressive pharmacologic management that risks cognitive / fall side effects.

MSA with retention​

Teach CIC early while dexterity remains; plan for SPC as progression limits function.

Clinical Correlations for the Reconstructive Urologist​

  • Differentiate PD from MSA. Early urinary retention with severe orthostasis + anal-sphincter EMG denervation = think MSA. This matters for prognosis and for avoiding futile outlet surgery.
  • β3 first, antimuscarinic second — in a cognitively vulnerable population, the anticholinergic burden of chronic oxybutynin is a real harm.
  • Urodynamics before outlet surgery in men with PD. OAB + BPH mix is common; operating without documenting obstruction leaves an unhappy patient.
  • CIC is often impractical in late PD. Plan drainage around that reality (SPC rather than ongoing CIC failure).
  • Functional incontinence is often bigger than neurogenic incontinence in late PD. Caregiver strategies, toilet transfer aids, clothing modifications, and scheduled voiding matter more than drugs.
  • MRI-compatibility and DBS coexistence drive implant selection.

References​

1. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult NLUTD: Treatment and Follow-Up." J Urol. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239

2. Panicker JN, Fowler CJ, Kessler TM. "Lower Urinary Tract Dysfunction in the Neurological Patient: Clinical Assessment and Management." Lancet Neurol. 2015;14(7):720–732. doi:10.1016/S1474-4422(15)00070-8